Prostate cancer. It's as common in men as breast cancer is in women, with 1 in 8 people developing the disease in their lifetime.

This makes it the most common non-skin cancer in men.

The good news? Prostate cancer is highly treatable, with an overall five-year relative survival rate of 98 percent and a nearly 100 percent survival rate when detected in the localized stage, according to the American Cancer Society.

The prostate-specific antigen (PSA) test has long been the go-to screening measure, but its results are sometimes used as the basis for an unnecessary treatment regimen because they can't tell physicians how aggressive the cancer is.

Screening guidelines have changed several times in recent years, so determining whether a PSA test is appropriate for someone can be confusing. Plus, most people have heard stories of unnecessary biopsies and treatment for prostate cancer following high PSA results.

Times have changed, though, and the tests available to detect prostate cancer have improved significantly. Some new assessments work in concert with a PSA test,